JP Morgan Chase’s Aligos Therapeutics ALGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.42K Buy
674
+368
+120% +$2.79K ﹤0.01% 6904
2025
Q4
$2.85K Sell
306
-402
-57% -$3.79K ﹤0.01% 6887
2025
Q3
$6.94K Buy
708
+682
+2,623% +$6.23K ﹤0.01% 6718
2025
Q2
$187 Hold
26
﹤0.01% 6787
2025
Q1
$215 Hold
26
﹤0.01% 6790
2024
Q4
$1.04K Hold
26
﹤0.01% 6725
2024
Q3
$225 Sell
26
-1
-4% -$12 ﹤0.01% 6894
2024
Q2
$237 Hold
27
﹤0.01% 6768
2024
Q1
$663 Hold
27
﹤0.01% 6684
2023
Q4
$450 Hold
27
﹤0.01% 6940
2023
Q3
$506 Hold
27
﹤0.01% 6725
2023
Q2
$657 Hold
27
﹤0.01% 6511
2023
Q1
$1K Hold
27
﹤0.01% 6486
2022
Q4
$1K Sell
27
-125
-82% -$3.15K ﹤0.01% 6372
2022
Q3
$5K Buy
152
+89
+141% +$2.96K ﹤0.01% 6082
2022
Q2
$2K Sell
63
-524
-89% -$17.8K ﹤0.01% 6270
2022
Q1
$31K Buy
587
+12
+2% +$961 ﹤0.01% 5946
2021
Q4
$170K Sell
575
-52
-8% -$19K ﹤0.01% 5438
2021
Q3
$244K Sell
627
-409
-39% -$162K ﹤0.01% 5129
2021
Q2
$529K Sell
1,036
-145
-12% -$92.4K ﹤0.01% 4660
2021
Q1
$672K Sell
1,181
-406
-26% -$270K ﹤0.01% 4491
2020
Q4
$1.1M Buy
+1,587
New +$773K ﹤0.01% 3900

Other funds holding ALGS

JP Morgan Chase's ALGS Position: Q1 2026 in Review

JP Morgan Chase increased its Aligos Therapeutics (ALGS) stake by 120% in Q1 2026, buying an estimated $2.79K and bringing the position to 674 shares worth $4.42K. The position accounts for ﹤0.01% of the portfolio, ranked #6904.

JP Morgan Chase first reported a position in ALGS in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.1M in Q4 2020. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • JP Morgan Chase held 674 shares of Aligos Therapeutics worth $4.42K as of Q1 2026.
  • JP Morgan Chase bought 368 Aligos Therapeutics shares in Q1 2026, an estimated $2.79K.
  • Aligos Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6904 holding.
  • JP Morgan Chase first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Aligos Therapeutics position peaked at $1.1M in Q4 2020.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.